128
Participants
Start Date
December 31, 2009
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2010
Aclidinium 400 μg / Formoterol 12 μg
Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
Aclidinium 400 μg / Formoterol 6 μg
Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
Aclidinium 400 μg
Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.
Formoterol 12 μg
Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.
Placebo
Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
Forest Investigative Site 1119, Elmira
Forest Investigative Site 1153, Raleigh
Forest Investigative Site 2035, Elizabeth City
Forest Investigative Site 1121, Spartanburg
Forest Investigative Site 2053, Tampa
Forest Investigative Site 2047, Tampa
Forest Investigative Site 1152, Clearwater
Forest Investigative Site 2028, Cincinnati
Forest Investigative Site 1129, Waco
Forest Investigative Site 1498, San Antonio
Forest Investigative Site 2045, Wheat Ridge
Forest Investigative Site 2050, Pheonix
Forest Investigative Site 0909, Glendale
Forest Investigative Site 2029, Rancho Mirage
Forest Investigative Site 1084, Stockton
Forest Investigative Site 1106, Portland
Forest Investigative Site 2043, Medford
Forest Investigative Site 1431, North Dartmouth
Forest Investigative Site 2084, Summit
Forest Investigative Site 1089, East Providence
Lead Sponsor
AstraZeneca
INDUSTRY